Clinical characteristics and outcomes of dialysis patients with atrial fibrillation: the Fushimi AF Registry

被引:14
作者
Yamashita, Yugo [1 ]
Takagi, Daisuke [2 ]
Hamatani, Yasuhiro [3 ]
Iguchi, Moritake [2 ]
Masunaga, Nobutoyo [2 ]
Esato, Masahiro [4 ]
Chun, Yeong-Hwa [4 ]
Itoh, Hitoshi [5 ]
Nishimura, Masato [6 ]
Wada, Hiromichi [7 ]
Hasegawa, Koji [7 ]
Ogawa, Hisashi [2 ]
Abe, Mitsuru [2 ]
Akao, Masaharu [2 ]
机构
[1] Kyoto Univ, Grad Sch Med, Dept Cardiovasc Med, Kyoto, Japan
[2] Natl Hosp Org Kyoto Med Ctr, Dept Cardiol, Fushimi Ku, 1-1 Mukaihata Cho, Kyoto 6128555, Japan
[3] Natl Cerebral & Cardiovasc Ctr, Div Heart Failure, Osaka, Japan
[4] Ijinkai Takeda Gen Hosp, Dept Arrhythmia, Kyoto, Japan
[5] Itoh Hemodialysis Clin, Kyoto, Japan
[6] Toujinkai Hosp, Cardiovasc Div, Kyoto, Japan
[7] Natl Hosp Org Kyoto Med Ctr, Div Translat Res, Kyoto, Japan
关键词
Atrial fibrillation; Dialysis; Stroke; Bleeding; Oral anticoagulant; STAGE RENAL-DISEASE; CHRONIC KIDNEY-DISEASE; HEMODIALYSIS-PATIENTS; RISK-FACTORS; WARFARIN INITIATION; PREDICTING STROKE; ISCHEMIC-STROKE; BLEEDING RISK; ANTICOAGULATION; MORTALITY;
D O I
10.1007/s00380-016-0818-x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Atrial fibrillation (AF) is common in dialysis patients. However, clinical characteristics and outcomes of dialysis patients with AF are poorly understood. The Fushimi AF Registry is a community-based prospective survey of AF patients in Japan. Follow-up data were available for 3713 patients with a median follow-up of 2.8 years. We compared clinical characteristics and outcomes between the dialysis group (n = 92; 2.5 %) and others. The dialysis group had more various co-morbidities, with a mean CHADS(2) score of 2.5, and the rate of warfarin prescription was 38 %. The annual incidence rates of stroke or systemic embolism (SE), major bleeding, and all-cause death in the dialysis group were 4.0, 5.1, and 20.9 per 100 person-years, respectively. There was no significant difference in the incidence rate of stroke/SE between the dialysis group and the non-dialysis group [hazard ratio (HR) 1.74 (95 % confidence interval (CI) 0.74-3.42)]. The incidence rates of major bleeding, all-cause death, and the composite of stroke/SE and all-cause death in the dialysis group were higher than those in the non-dialysis group [major bleeding: HR 3.09 (95 % CI 1.46-5.72), all-cause death: HR 3.51 (95 % CI 2.48-4.81), the composite of stroke/SE and all-cause death: HR 2.99 (95 % CI 2.15-4.05)]. Among dialysis patients, warfarin did not affect major clinical events including stroke/SE, bleeding or all-cause death. Among AF patients, those receiving dialysis showed higher incidence of major bleeding and all-cause death compared with non-dialysis patients, but the risk of stroke/SE was not particularly high. URL: www.umin.ac.jp/ctr/index.htm http://www.umin.ac.jp/ctr/index.htm" TargetType="URL.
引用
收藏
页码:2025 / 2034
页数:10
相关论文
共 38 条
[1]   Inappropriate Use of Oral Anticoagulants for Patients With Atrial Fibrillation-1-Year Outcomes of the Fushimi AF Registry [J].
Akao, Masaharu ;
Chun, Yeong-Hwa ;
Esato, Masahiro ;
Abe, Mitsuru ;
Tsuji, Hikari ;
Wada, Hiromichi ;
Hasegawa, Koji .
CIRCULATION JOURNAL, 2014, 78 (09) :2166-2172
[2]   Current status of clinical background of patients with atrial fibrillation in a community-based survey: The Fushimi AF Registry [J].
Akao, Masaharu ;
Chun, Yeong-Hwa ;
Wada, Hiromichi ;
Esato, Masahiro ;
Hashimoto, Tetsuo ;
Abe, Mitsuru ;
Hasegawa, Koji ;
Tsuji, Hikari ;
Furuke, Keizo .
JOURNAL OF CARDIOLOGY, 2013, 61 (3-4) :260-266
[3]   Management of Patients With Atrial Fibrillation (Compilation of 2006 ACCF/AHA/ESC and 2011 ACCF/AHA/HRS Recommendations) A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines [J].
Anderson, Jeffrey L. ;
Halperin, Jonathan L. ;
Albert, Nancy M. ;
Bozkurt, Biykem ;
Brindis, Ralph G. ;
Curtis, Lesley H. ;
DeMets, David ;
Guyton, Robert A. ;
Hochman, Judith S. ;
Kovacs, Richard J. ;
Ohman, E. Magnus ;
Pressler, Susan J. ;
Sellke, Frank W. ;
Shen, Win-Kuang .
CIRCULATION, 2013, 127 (18) :1916-1926
[4]  
Camm AJ, 2012, EUROPACE, V14, P1385, DOI [10.1093/europace/eus305, 10.1093/eurheartj/ehs253]
[5]   Dabigatran and Rivaroxaban Use in Atrial Fibrillation Patients on Hemodialysis [J].
Chan, Kevin E. ;
Edelman, Elazer R. ;
Wenger, Julia B. ;
Thadhani, Ravi I. ;
Maddux, Franklin W. .
CIRCULATION, 2015, 131 (11) :972-979
[6]   Warfarin Use Associates with Increased Risk for Stroke in Hemodialysis Patients with Atrial Fibrillation [J].
Chan, Kevin E. ;
Lazarus, J. Michael ;
Thadhani, Ravi ;
Hakim, Raymond M. .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2009, 20 (10) :2223-2233
[7]   Anticoagulant and Antiplatelet Usage Associates with Mortality among Hemodialysis Patients [J].
Chan, Kevin E. ;
Lazarus, J. Michael ;
Thadhani, Ravi ;
Hakim, Raymond M. .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2009, 20 (04) :872-881
[8]  
Chao TF, 2014, HEART RHYTHM, V11, P1752, DOI [10.1016/j.hrthm.20l4.06.021, 10.1016/j.hrthm.2014.06.021]
[9]   Should patients with advanced chronic kidney disease and atrial fibrillation receive chronic anticoagulation? [J].
Clase, Catherine M. ;
Holden, Rachel M. ;
Sood, Manish M. ;
Rigatto, Claudio ;
Moist, Louise M. ;
Thomson, Benjamin K. A. ;
Mann, Johannes F. E. ;
Zimmerman, Deborah L. .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2012, 27 (10) :3719-3724
[10]   Stroke, Major Bleeding, and Mortality Outcomes in Warfarin Users With Atrial Fibrillation and Chronic Kidney Disease A Meta-Analysis of Observational Studies [J].
Dahal, Khagendra ;
Kunwar, Sumit ;
Rijal, Jharendra ;
Schulman, Peter ;
Lee, Juyong .
CHEST, 2016, 149 (04) :951-959